Psychemedics Corporation (PMD)
USD 2.67
(0.0%)
USD 2.67
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.92 Million USD | -169.71% |
| 2022 | -1.08 Million USD | 68.89% |
| 2021 | -3.48 Million USD | 42.61% |
| 2020 | -6.06 Million USD | -7321.43% |
| 2019 | 84 Thousand USD | -98.9% |
| 2018 | 7.65 Million USD | -6.18% |
| 2017 | 8.15 Million USD | -19.32% |
| 2016 | 10.11 Million USD | 587.11% |
| 2015 | 1.47 Million USD | -68.62% |
| 2014 | 4.68 Million USD | -17.82% |
| 2013 | 5.7 Million USD | 15.61% |
| 2012 | 4.93 Million USD | -14.91% |
| 2011 | 5.8 Million USD | 31.4% |
| 2010 | 4.41 Million USD | 70.82% |
| 2009 | 2.58 Million USD | -45.09% |
| 2008 | 4.7 Million USD | -34.07% |
| 2007 | 7.13 Million USD | -5.61% |
| 2006 | 7.56 Million USD | 19.55% |
| 2005 | 6.32 Million USD | 46.07% |
| 2004 | 4.33 Million USD | 123.49% |
| 2003 | 1.93 Million USD | 0.1% |
| 2002 | 1.93 Million USD | 499.02% |
| 2001 | 323.19 Thousand USD | -86.7% |
| 2000 | 2.42 Million USD | -30.58% |
| 1999 | 3.5 Million USD | 6.06% |
| 1998 | 3.3 Million USD | 10.0% |
| 1997 | 3 Million USD | 25.0% |
| 1996 | 2.4 Million USD | 100.0% |
| 1995 | 1.2 Million USD | -33.33% |
| 1994 | 1.8 Million USD | 80.0% |
| 1993 | 1 Million USD | 300.0% |
| 1992 | -500 Thousand USD | 64.29% |
| 1991 | -1.4 Million USD | 33.33% |
| 1990 | -2.1 Million USD | -90.91% |
| 1989 | -1.1 Million USD | 45.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -567 Thousand USD | 34.68% |
| 2024 Q2 | -899 Thousand USD | -58.55% |
| 2023 Q4 | -868 Thousand USD | 21.59% |
| 2023 Q2 | -417 Thousand USD | 21.02% |
| 2023 Q1 | -528 Thousand USD | -48.31% |
| 2023 Q3 | -1.1 Million USD | -165.47% |
| 2023 FY | -2.92 Million USD | -169.71% |
| 2022 Q3 | -375 Thousand USD | -9.65% |
| 2022 Q1 | -10 Thousand USD | 98.96% |
| 2022 Q2 | -342 Thousand USD | -3320.0% |
| 2022 Q4 | -356 Thousand USD | 5.07% |
| 2022 FY | -1.08 Million USD | 68.89% |
| 2021 Q4 | -965 Thousand USD | -213.53% |
| 2021 Q2 | 207 Thousand USD | 76.92% |
| 2021 Q3 | 850 Thousand USD | 310.63% |
| 2021 FY | -3.48 Million USD | 42.61% |
| 2021 Q1 | 117 Thousand USD | 110.55% |
| 2020 FY | -6.06 Million USD | -7321.43% |
| 2020 Q4 | -1.1 Million USD | 21.29% |
| 2020 Q3 | -1.4 Million USD | 57.38% |
| 2020 Q2 | -3.3 Million USD | -1266.12% |
| 2020 Q1 | -242 Thousand USD | 60.07% |
| 2019 FY | 84 Thousand USD | -98.9% |
| 2019 Q2 | 1.32 Million USD | 40.47% |
| 2019 Q3 | 1.33 Million USD | 0.6% |
| 2019 Q4 | -606 Thousand USD | -145.43% |
| 2019 Q1 | 944 Thousand USD | -38.22% |
| 2018 FY | 7.65 Million USD | -6.18% |
| 2018 Q2 | 2.05 Million USD | 7.87% |
| 2018 Q1 | 1.9 Million USD | -2.11% |
| 2018 Q3 | 2.12 Million USD | 3.11% |
| 2018 Q4 | 1.52 Million USD | -27.92% |
| 2017 FY | 8.15 Million USD | -19.32% |
| 2017 Q4 | 1.94 Million USD | -12.77% |
| 2017 Q1 | 2.26 Million USD | -37.64% |
| 2017 Q2 | 1.71 Million USD | -24.6% |
| 2017 Q3 | 2.23 Million USD | 30.53% |
| 2016 Q4 | 3.63 Million USD | -11.38% |
| 2016 FY | 10.11 Million USD | 587.11% |
| 2016 Q3 | 4.1 Million USD | 73.08% |
| 2016 Q2 | 2.37 Million USD | 135981.43% |
| 2016 Q1 | -1745.00 USD | -101.54% |
| 2015 Q2 | 356.04 Thousand USD | -20.97% |
| 2015 Q1 | 450.51 Thousand USD | -52.96% |
| 2015 FY | 1.47 Million USD | -68.62% |
| 2015 Q3 | 551.18 Thousand USD | 54.81% |
| 2015 Q4 | 113.63 Thousand USD | -79.38% |
| 2014 FY | 4.68 Million USD | -17.82% |
| 2014 Q1 | 1.16 Million USD | 13.06% |
| 2014 Q3 | 1.24 Million USD | -5.72% |
| 2014 Q4 | 957.67 Thousand USD | -23.03% |
| 2014 Q2 | 1.31 Million USD | 12.98% |
| 2013 Q4 | 1.03 Million USD | -40.6% |
| 2013 Q1 | 1.2 Million USD | 159.22% |
| 2013 Q3 | 1.73 Million USD | 0.44% |
| 2013 Q2 | 1.73 Million USD | 44.05% |
| 2013 FY | 5.7 Million USD | 15.61% |
| 2012 Q3 | 1.43 Million USD | -14.01% |
| 2012 Q2 | 1.66 Million USD | 20.87% |
| 2012 Q1 | 1.37 Million USD | 84.82% |
| 2012 FY | 4.93 Million USD | -14.91% |
| 2012 Q4 | 463.77 Thousand USD | -67.59% |
| 2011 Q3 | 1.8 Million USD | 2.81% |
| 2011 Q4 | 744.96 Thousand USD | -58.78% |
| 2011 Q1 | 1.49 Million USD | 119.85% |
| 2011 FY | 5.8 Million USD | 31.4% |
| 2011 Q2 | 1.75 Million USD | 17.98% |
| 2010 Q1 | 835.86 Thousand USD | -12.95% |
| 2010 Q4 | 677.76 Thousand USD | -49.28% |
| 2010 Q3 | 1.33 Million USD | -14.58% |
| 2010 FY | 4.41 Million USD | 70.82% |
| 2010 Q2 | 1.56 Million USD | 87.17% |
| 2009 FY | 2.58 Million USD | -45.09% |
| 2009 Q4 | 960.26 Thousand USD | -24.57% |
| 2009 Q3 | 1.27 Million USD | 327.2% |
| 2009 Q2 | 298 Thousand USD | 463.12% |
| 2009 Q1 | 52.92 Thousand USD | -82.16% |
| 2008 Q4 | 296.66 Thousand USD | -78.32% |
| 2008 Q2 | 1.65 Million USD | 19.96% |
| 2008 Q1 | 1.38 Million USD | -6.64% |
| 2008 FY | 4.7 Million USD | -34.07% |
| 2008 Q3 | 1.36 Million USD | -17.5% |
| 2007 Q1 | 1.63 Million USD | -9.48% |
| 2007 Q2 | 2.11 Million USD | 29.62% |
| 2007 Q3 | 1.91 Million USD | -9.39% |
| 2007 Q4 | 1.48 Million USD | -22.62% |
| 2007 FY | 7.13 Million USD | -5.61% |
| 2006 Q1 | 1.4 Million USD | -0.45% |
| 2006 Q4 | 1.8 Million USD | -17.7% |
| 2006 FY | 7.56 Million USD | 19.55% |
| 2006 Q3 | 2.18 Million USD | 1.04% |
| 2006 Q2 | 2.16 Million USD | 53.76% |
| 2005 Q3 | 1.52 Million USD | -18.78% |
| 2005 FY | 6.32 Million USD | 46.07% |
| 2005 Q4 | 1.41 Million USD | -7.49% |
| 2005 Q2 | 1.88 Million USD | 25.59% |
| 2005 Q1 | 1.49 Million USD | 73.23% |
| 2004 Q4 | 865.49 Thousand USD | -28.05% |
| 2004 FY | 4.33 Million USD | 123.49% |
| 2004 Q3 | 1.2 Million USD | -21.83% |
| 2004 Q2 | 1.53 Million USD | 112.6% |
| 2004 Q1 | 723.81 Thousand USD | 43.63% |
| 2003 Q4 | 503.96 Thousand USD | -15.0% |
| 2003 FY | 1.93 Million USD | 0.1% |
| 2003 Q3 | 592.87 Thousand USD | -11.9% |
| 2003 Q1 | 168.16 Thousand USD | 274.67% |
| 2003 Q2 | 672.94 Thousand USD | 300.17% |
| 2002 Q4 | 44.88 Thousand USD | -93.86% |
| 2002 Q1 | 88.83 Thousand USD | 123.65% |
| 2002 FY | 1.93 Million USD | 499.02% |
| 2002 Q2 | 1.07 Million USD | 1106.07% |
| 2002 Q3 | 730.84 Thousand USD | -31.79% |
| 2001 Q4 | -375.61 Thousand USD | -303.68% |
| 2001 Q3 | 184.41 Thousand USD | -65.35% |
| 2001 FY | 323.19 Thousand USD | -86.7% |
| 2001 Q1 | -17.8 Thousand USD | 48.04% |
| 2001 Q2 | 532.19 Thousand USD | 3089.52% |
| 2000 Q4 | -34.25 Thousand USD | -104.83% |
| 2000 Q2 | 1.09 Million USD | 65.77% |
| 2000 FY | 2.42 Million USD | -30.58% |
| 2000 Q1 | 660.39 Thousand USD | 230.2% |
| 2000 Q3 | 708.8 Thousand USD | -35.26% |
| 1999 Q1 | 900 Thousand USD | 125.0% |
| 1999 Q2 | 1.6 Million USD | 77.78% |
| 1999 Q3 | 1 Million USD | -37.5% |
| 1999 Q4 | 200 Thousand USD | -80.0% |
| 1999 FY | 3.5 Million USD | 6.06% |
| 1998 Q4 | 400 Thousand USD | -60.0% |
| 1998 Q1 | 900 Thousand USD | 0.0% |
| 1998 Q2 | 1.1 Million USD | 22.22% |
| 1998 FY | 3.3 Million USD | 10.0% |
| 1998 Q3 | 1 Million USD | -9.09% |
| 1997 Q1 | 700 Thousand USD | 40.0% |
| 1997 FY | 3 Million USD | 25.0% |
| 1997 Q2 | 1 Million USD | 42.86% |
| 1997 Q4 | 900 Thousand USD | 80.0% |
| 1997 Q3 | 500 Thousand USD | -50.0% |
| 1996 Q1 | 400 Thousand USD | 500.0% |
| 1996 FY | 2.4 Million USD | 100.0% |
| 1996 Q4 | 500 Thousand USD | -28.57% |
| 1996 Q3 | 700 Thousand USD | 0.0% |
| 1996 Q2 | 700 Thousand USD | 75.0% |
| 1995 Q2 | 600 Thousand USD | 100.0% |
| 1995 Q4 | -100 Thousand USD | -120.0% |
| 1995 Q3 | 500 Thousand USD | -16.67% |
| 1995 Q1 | 300 Thousand USD | -50.0% |
| 1995 FY | 1.2 Million USD | -33.33% |
| 1994 Q3 | 600 Thousand USD | 0.0% |
| 1994 Q4 | 600 Thousand USD | 0.0% |
| 1994 FY | 1.8 Million USD | 80.0% |
| 1994 Q2 | 600 Thousand USD | 0.0% |
| 1994 Q1 | - USD | -100.0% |
| 1993 Q1 | -200 Thousand USD | 94.12% |
| 1993 Q2 | 200 Thousand USD | 200.0% |
| 1993 Q3 | 300 Thousand USD | 50.0% |
| 1993 Q4 | 600 Thousand USD | 100.0% |
| 1993 FY | 1 Million USD | 300.0% |
| 1992 FY | -500 Thousand USD | 64.29% |
| 1992 Q3 | 1.2 Million USD | 20.0% |
| 1992 Q2 | 1 Million USD | 350.0% |
| 1992 Q1 | -400 Thousand USD | 87.5% |
| 1992 Q4 | -3.4 Million USD | -383.33% |
| 1991 FY | -1.4 Million USD | 33.33% |
| 1991 Q3 | 700 Thousand USD | 16.67% |
| 1991 Q4 | -3.2 Million USD | -557.14% |
| 1991 Q2 | 600 Thousand USD | 250.0% |
| 1991 Q1 | -400 Thousand USD | 87.5% |
| 1990 Q3 | 600 Thousand USD | 50.0% |
| 1990 Q2 | 400 Thousand USD | 100.0% |
| 1990 FY | -2.1 Million USD | -90.91% |
| 1990 Q1 | 200 Thousand USD | 0.0% |
| 1990 Q4 | -3.2 Million USD | -633.33% |
| 1989 Q2 | -1.1 Million USD | -466.67% |
| 1989 Q3 | 100 Thousand USD | 109.09% |
| 1989 FY | -1.1 Million USD | 45.0% |
| 1989 Q1 | 300 Thousand USD | 50.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 97.0% |
| Biodesix, Inc. | -41.34 Million USD | 92.935% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 63.365% |
| Castle Biosciences, Inc. | -67.97 Million USD | 95.703% |
| DarioHealth Corp. | -56.18 Million USD | 94.801% |
| Exact Sciences Corporation | -215.01 Million USD | 98.641% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 100.266% |
| Illumina, Inc. | -1.06 Billion USD | 99.727% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 71.594% |
| iSpecimen Inc. | -11.16 Million USD | 73.848% |
| Standard BioTools Inc. | -76.6 Million USD | 96.187% |
| 23andMe Holding Co. | -321.35 Million USD | 99.091% |
| Medpace Holdings, Inc. | 336.82 Million USD | 100.867% |
| NeoGenomics, Inc. | -107.73 Million USD | 97.289% |
| Inotiv, Inc. | -81.46 Million USD | 96.414% |
| Precipio, Inc. | -7.62 Million USD | 61.667% |
| RadNet, Inc. | 98.69 Million USD | 102.96% |
| Sotera Health Company | 276.69 Million USD | 101.056% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 32.789% |
| Prenetics Global Limited | -52.51 Million USD | 94.438% |
| Exagen Inc. | -22.83 Million USD | 87.209% |
| Natera, Inc. | -446.24 Million USD | 99.345% |
| Aspira Women's Health Inc. | -18.85 Million USD | 84.506% |
| Neogen Corporation | 58.66 Million USD | 104.979% |
| Myriad Genetics, Inc. | -123.7 Million USD | 97.639% |
| ICON Public Limited Company | 956.15 Million USD | 100.305% |
| Bionano Genomics, Inc. | -215.24 Million USD | 98.643% |
| CareDx, Inc | -101.9 Million USD | 97.133% |
| Check-Cap Ltd. | -19.28 Million USD | 84.855% |
| Twist Bioscience Corporation | -220.83 Million USD | 98.677% |
| Guardant Health, Inc. | -564.72 Million USD | 99.483% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -12.624% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 95.982% |
| Sera Prognostics, Inc. | -39.82 Million USD | 92.665% |
| OPKO Health, Inc. | -157.02 Million USD | 98.14% |
| Personalis, Inc. | -109.93 Million USD | 97.343% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 73.332% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 32.789% |
| MDxHealth SA | -27.32 Million USD | 89.311% |
| Prenetics Global Limited | -52.51 Million USD | 94.438% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 72.236% |
| Mainz Biomed B.V. | -26.64 Million USD | 89.037% |
| Trinity Biotech plc | -27.04 Million USD | 89.199% |
| Neuronetics, Inc. | -30.55 Million USD | 90.44% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 63.365% |